Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
A recent paper by Emmy Boerrigter, Pharmacist at Radboudumc Research Institute for Medical Innovation, was mentioned by European Urology Oncology on X:
“A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with PCa by Emmy Boerrigter, Joanneke K. Overbeek et al.”
Authors: Emmy Boerrigter, Joanneke Overbeek, Guillemette Benoist, Inge van Oort, Nielka van Erp et al.
More posts featuring European Urology Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 30, 2024, 13:23
Dec 30, 2024, 12:58
Dec 30, 2024, 12:36